Survival adjusting for crossover: phase 3 study of ibrutinib vs chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Steven Coutre,Alessandra Tedeschi,Tadeusz Robak,Paul M Barr,Carolyn Owen,Osnat Bairey,Jan Burger,Cathy Zhou,Lori Styles,Danelle F James,Thomas J Kipps

HAEMATOLOGICA（2018）

引用 6|浏览27

暂无评分

摘要

Ibrutinib, a first-in-class, once-daily inhibitor of Bruton’s tyrosine kinase, is indicated by the US FDA for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and allows for treatment without chemotherapy. This broad approval, including treatment-na

查看译文

关键词

Bruton's tyrosine kinase inhibitor,Chronic Lymphocytic Leukemia,Ibrutinib,Overall survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要